Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis

Figures

• 

  Figure 1. Study selection flow. DOACs, direct oral anticoagulants; VKAs, vitamin K antagonists;CEVR, Centre for Evaluation of Value and Risks in Health databases.

• 

  Figure 2. Summary of the pooled INBs of DOACs compared with VKAs classified by country income and perspectives. DOACs, direct oral anticoagulants; HICs, high-income countries; INBs, incremental net benefits; SP, societal perspective; TPP, third-party payer; UMICs, upper-middle income countries; VKAs, vitamin K antagonists.